Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis
- PMID: 17914985
- DOI: 10.1111/j.1440-1746.2006.04735.x
Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis
Erratum in
- J Gastroenterol Hepatol. 2007 Oct;22(10):1697
Abstract
Background and aim: The molecular mechanisms underlying the involvement of the renin-angiotensin system in hepatic fibrosis are unclear. Recently, it was reported that a Rho kinase inhibitor prevented fibrosis of various tissues and that the Rho/Rho kinase pathway was involved in the renin-angiotensin system of vascular smooth muscle cells. In this study, the involvement of the Rho/Rho kinase pathway on angiotensin II signaling in liver fibrogenesis and generation of steatosis was investigated.
Methods: Rats were fed a choline-deficient/L-amino acid-defined (CDAA) diet continuously and treated with a Rho kinase inhibitor, Y-27632, and an angiotensin II receptor blocker, TCV-116. Liver histology and hepatic stellate cell activation were analyzed. Free radical production was detected by 4-hydroxynonenal and 8-hydroxy-2'-deoxyguanosine immunostaining and the expression of tumor necrosis factor-alpha was examined. Isolated hepatic stellate cells were pretreated with a Rho kinase inhibitor, Y-27632, or an angiotensin II receptor blocker, CV-11974, and stimulated with angiotensin II, and mRNA expression of transforming growth factor-beta and alpha-smooth muscle actin was analyzed.
Results: Both the angiotensin II receptor blocker and the Rho kinase inhibitor improved fibrosis and steatosis of the liver in CDAA-fed rats. The increase in the number of hepatocytes positive for 4-hydroxynonenal and 8-hydroxy-2'-deoxyguanosine in CDAA-fed rats was significantly prevented by the angiotensin II receptor blocker and the Rho kinase inhibitor. The levels of tumor necrosis factor-alpha mRNA in the liver of CDAA-fed rats were significantly increased and this increase was significantly inhibited by treatment with the angiotensin II receptor blocker and the Rho kinase inhibitor. mRNA expression of transforming growth factor-beta and alpha-smooth muscle actin stimulated by angiotensin II was also significantly suppressed by these two drugs.
Conclusion: These results suggest that the Rho/Rho kinase pathway is at least partly involved in the renin-angiotensin system and plays an important role in hepatic fibrosis and steatosis.
Similar articles
-
Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.Eur J Pharmacol. 2008 Jul 7;588(2-3):316-24. doi: 10.1016/j.ejphar.2008.04.028. Epub 2008 Apr 16. Eur J Pharmacol. 2008. PMID: 18501344
-
Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice.Int J Mol Med. 2012 Jul;30(1):107-13. doi: 10.3892/ijmm.2012.958. Epub 2012 Apr 2. Int J Mol Med. 2012. PMID: 22469867
-
Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.Liver Int. 2009 Aug;29(7):988-96. doi: 10.1111/j.1478-3231.2009.02006.x. Epub 2009 Apr 6. Liver Int. 2009. PMID: 19386026
-
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?Adv Ther. 2008 Nov;25(11):1141-74. doi: 10.1007/s12325-008-0110-2. Adv Ther. 2008. PMID: 18972077 Review.
-
Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling.Nitric Oxide. 2014 Dec 1;43:45-54. doi: 10.1016/j.niox.2014.09.002. Epub 2014 Sep 6. Nitric Oxide. 2014. PMID: 25196952 Review.
Cited by
-
Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.J Clin Invest. 2018 Dec 3;128(12):5335-5350. doi: 10.1172/JCI63562. Epub 2018 Oct 29. J Clin Invest. 2018. PMID: 30226474 Free PMC article.
-
Carvedilol Inhibits Angiotensin II-Induced Proliferation and Contraction in Hepatic Stellate Cells through the RhoA/Rho-Kinase Pathway.Biomed Res Int. 2019 Nov 7;2019:7932046. doi: 10.1155/2019/7932046. eCollection 2019. Biomed Res Int. 2019. PMID: 31828132 Free PMC article.
-
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.Br J Pharmacol. 2009 May;157(2):258-70. doi: 10.1111/j.1476-5381.2009.00158.x. Epub 2009 Mar 26. Br J Pharmacol. 2009. PMID: 19338580 Free PMC article.
-
The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells.PLoS One. 2023 Jan 31;18(1):e0270288. doi: 10.1371/journal.pone.0270288. eCollection 2023. PLoS One. 2023. PMID: 36719899 Free PMC article.
-
Preventive effect of Qianggan-Rongxian Decoction on rat liver fibrosis.World J Gastroenterol. 2008 Jun 14;14(22):3569-73. doi: 10.3748/wjg.14.3569. World J Gastroenterol. 2008. PMID: 18567088 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical